Market Overview

Uncertainty Around Iqvia's Near-Term Earnings Path Is Clearing, Goldman Sachs Says In Upgrade

Share:
Uncertainty Around Iqvia's Near-Term Earnings Path Is Clearing, Goldman Sachs Says In Upgrade
Related
Earnings Scheduled For October 22, 2018
BofA Upgrades Iqvia On Upside Potential

In a preview of the first-quarter results of contract research organizations,Goldman Sachs said the group remains attractive with a healthy fundamental backdrop and no material signs of a trend reversal in 2018. 

The firm also turned bullish on Iqvia Holdings Inc (NYSE: IQV).

The Analyst

Analyst Robert Jones upgraded shares of Iqvia from Neutral to Buy and nudged down the price target from $115 to $114.

The Thesis

CROs as a group have underperformed the S&P 500 Index year-to-date, dragged by fears of large-scale pharma M&A in the wake of corporate tax reform, Jones said in a Friday note. The CRO stock weakness is still overblown in Jones' view, as he said he projects only muted impacts to CROs.

"At the same time, the flow of public and private biotech funding remain well above historical averages (with private funding in particular at record levels as of 1Q18) and we see global pharma R&D budgets at a healthy mid-single digit clip despite some recent trial result missteps," the analyst said.

Although optimistic on the longer-term potential of Iqvia's unique combination of data assets and its clinical CRO offering, the analyst said he was previously sidelined due to the uncertainty around the Durham, North Carolina company's near-term earnings trajectory. 

The near-term stage is now cleared for a beat on conservative guidance in 2018, even without revenue synergies hitting the P&L, Jones said. 

Signs of Iqvia's "smarter CRO" moving the needle are compelling, although the Street is not assigning much value to it, the analyst said. 

The analyst said he is even less concerned about pharma M&A for Iqvia, as its CRO client base is more diversified than peers. The impact on the company's commercial business is likely negligible, even in a hypothetical mega-merger scenario, the analyst said. 

The Price Action

Iqvia shares have added about 22 percent over the past year. The equity was up 1.62 percent at the time of publication Friday.

Related Links:

8 Biotech Stocks With Clinical Trial Outcomes In April

Halyard Health Has 34% Upside Potential, KeyBanc Says In Upgrade

Latest Ratings for IQV

DateFirmActionFromTo
Oct 2018BarclaysMaintainsOverweightOverweight
Aug 2018Raymond JamesMaintainsStrong BuyStrong Buy
Aug 2018Wells FargoMaintainsOutperformOutperform

View More Analyst Ratings for IQV
View the Latest Analyst Ratings

Posted-In: Contract Research Organization CROAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (IQV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

You Can Rescue Medical Breakthroughs From The Valley Of Death

Another Russia Controversy Sparks Activity In These ETFs